Revised Scoping Document

PDF cover

Asthma: Revised Scoping Document

The proposed scope for ICER’s initial draft report on mepolizumab (Nucala, GlaxoSmithKline plc.) for the treatment of severe eosinophilic asthma.¬†This version of the scope incorporates feedback from a one week public comment period.


View All Materials on this Topic or Go Back to View More Materials